ctDNA-based monitoring provides clarity beyond traditional imaging.
RADIOHEAD: 644 STAGE IV CANCER PATIENTS 1,761 TISSUE-FREE SAMPLES DRAWN ACROSS 4 TIMEPOINTS | MULTIPLE SOLID TUMORS1
ctDNA, circulating tumor DNA; IO, immunotherapy
References: 1. Liang SI, Quandt Z. Wienke S, et al. Methylation-based ctDNA tumor fraction changes predict long-term clinical benefit from immune checkpoint inhibitors in RADIOHEAD, a real-world pan-cancer study. Cancer Res Commun. 2025.
ctDNA-based monitoring provides clarity beyond traditional imaging.
RADIOHEAD: 644 STAGE IV CANCER PATIENTS 1,761 TISSUE-FREE SAMPLES DRAWN ACROSS 4 TIMEPOINTS | MULTIPLE SOLID TUMORS1
ctDNA, circulating tumor DNA; IO, immunotherapy